Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 2195 • 2015 ACR/ARHP Annual Meeting
Long Term Outcome of Primary Antiphospholipid Syndrome Patients: A Multicenter Study
Francesca Dall'Ara¹, Mara Taraborelli², Rossella Reggia¹, Micaela Fredi², Maria Gerosa³, Laura Massaro⁴, Ariela Hoxha⁵, Marta Tonello⁵, Patrice Cacoub⁶, Nathalie Costedoat-Chalumeau⁷, Franco Franceschini², Pier Luigi Meroni⁸, Jean Charles Piette⁶, Amelia Ruffatti⁵, Guido Valesini⁴ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ³Division of Rheumatology, Department of Clinical Sciences and Community Health, Ospedale Gaetano Pini, University of Milan, Milano, Italy, ⁴Internal Medicine and Medical Specialties Department, Policlinico Umberto I, La Sapienza University of Rome, Roma, Italy, ⁵Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, ⁶Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ⁷Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁸Division of Rheumatology, Division of Rheumatology, Istituto Ortopedico Gaetano Pini, Milan, Italy
Background/Purpose: Data on the long-term outcome in primary antiphospholipid syndrome (PAPS) patients (pt) are still very limited.The objectives of this work was to assess the…
Abstract Number: 2199 • 2015 ACR/ARHP Annual Meeting
in Vivo Ubiquinol Supplementation Reduces the Pro-Atherothrombotic Status in Antiphospholipid Syndrome Patients. Preliminary Results of a Clinical Trial
Chary Lopez-Pedrera¹, Maria Ángeles Aguirre Zamorano¹, Francisco Velasco², Patricia Ruiz-Limon¹, Nuria Barbarroja¹, Yolanda Jiménez Gómez¹, Maria Carmen Abalos-Aguilera¹, Pedro Segui³, Eduardo Collantes-Estevez¹, Lucia Fernandez-del Rio⁴, Jose Antonio Gonzalez-Reyes⁴, Jose Manuel Villalba⁴, Mª Jose Cuadrado⁵ and Carlos Perez-Sanchez¹, ¹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²Hematology, IMIBIC-Reina Sofia Hospital, Hematology Unit, Cordoba, Spain, ³IMIBIC-Reina Sofia University Hospital, Radiology Unit, Cordoba, Spain, ⁴Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain, ⁵Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom
Background/Purpose: To investigate the beneficial effects of in vivoubiquinol (Q, reduced form of CoQ10) supplementation on athero-thrombosis prevention in APS patients, through the implementation of…
Abstract Number: 2201 • 2015 ACR/ARHP Annual Meeting
Triple Positivity of Antiphospholipid Antibody As the Main Thrombotic Factor in a Long-Term Follow-up Study of 98 Asymptomatic Apl-Positive Carriers
Cécile Yelnik^1,2, Elodie Drumez³, Sylvain Dubucquoi^2,4,5, Vincent Sobanski^1,2,4, Hélène Maillard^1,6, Alain Duhamel³, David Launay^1,2,4, Eric Hachulla^1,2,4, Pierre-Yves Hatron^1,2 and Marc Lambert^1,2,4, ¹Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ²Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ³CERIM, Université Lille Nord de France, Lille, France, ⁴LIRIC, INSERM UMR 995, Lille, France, ⁵Institut d’Immunologie, Centre de Biologie-Pathologie-Génétique, CHRU Lille, Lille, France, ⁶Faculté de Médecine Henri Warembourg, Université Lille Nord de France, lille, France
Background/Purpose: There is limited data regarding the long-term risk of developing a first-time thrombotic event and prophylactic benefits of aspirin use in asymptomatic aPL-positive carriers.…
Abstract Number: 2919 • 2015 ACR/ARHP Annual Meeting
Effect of Thrombotic Microangiopathy on Clinical Outcomes in LUPUS Nephritis
Krishan Gupta¹, Manish Rathi², Navin Pattanashetti³, Ritambhra Nada⁴ and Aman Sharma⁵, ¹Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³Internal Medicine, Junior Resident, Chandigarh, India, ⁴Histopathology, Professor, Chandigarh, India, ⁵Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: In addition to glomerular lesion, renal vascular lesion is also an important prognostic marker of lupus nephritis (LN). Among various vascular changes thrombotic microangiopathy…
Abstract Number: 1854 • 2015 ACR/ARHP Annual Meeting
Identification and Characterization of microRNAs Related to the Pathogenesis of Cardiovascular Disease in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Role of Specific Autoantibodies
Chary Lopez-Pedrera¹, Maria Ángeles Aguirre Zamorano¹, Patricia Ruiz-Limon¹, Nuria Barbarroja¹, Yolanda Jiménez Gómez¹, Eduardo Collantes-Estevez¹, Mª Jose Cuadrado², Rocio Gonzalez-Conejero³, Constantino Martinez³ and Carlos Perez-Sanchez¹, ¹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ³Regional Centre for Blood Donation, University of Murcia, Murcia, Spain
Background/Purpose: 1) To identify and characterize miRNAs related to the pathogenesis of CVD in antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) patients; 2) To…
Abstract Number: 2945 • 2015 ACR/ARHP Annual Meeting
Diffuse Alveolar Hemorrhage in SLE: Risk Factors, Response to Therapy, and Survival
Nayef M. Kazzaz¹, Patrick S. Coit², Emily E. Lewis³, W Joseph McCune⁴, Amr H. Sawalha² and Jason S. Knight², ¹Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI, ⁴Int Med/ Rheum, University of Michigan, Ann Arbor, MI
Background/Purpose: While diffuse alveolar hemorrhage (DAH) is recognized as a life-threatening complication of SLE, little is known about its risk factors and response to therapy. …
Abstract Number: 2000 • 2015 ACR/ARHP Annual Meeting
Immune Response Against Â Î²2GPI Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome
Pier Luigi Meroni^1,2, Marisa Benagiano³, Maria Gerosa⁴, Jacopo Romagnoli⁵, Michael Mahler⁶, Maria Orietta Borghi^7,8, Alessia Grassi⁹, Chiara Della Bella³, Giacomo Emmi³, Amedeo Amedei^3,10, Elena Silvestri³, Lorenzo Emmi¹¹, Domenico Prisco^9,10 and Mario Milco D'Elios^3,10, ¹Clinical Sciences and Community Heath, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ²Laboratory of Immuno-rheumatology, Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Italy, ³Department of Experimental and Clinical Medicine, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁴Division of Rheumatology, Department of Clinical Sciences and Community Health, Ospedale Gaetano Pini, University of Milan, Milano, Italy, ⁵Department of Surgery, Department of Surgery, Catholic University of Rome, Rome, Italy, ⁶Inova Diagnostics, San Diego, CA, ⁷Department of Clinical Sciences and Community Health, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁸Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁹Department of Experimental and Clinical Medicine,, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ¹⁰Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic, Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic, AOU Careggi, Florence, Italy, ¹¹Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic,, Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic, AOU Careggi, Florence, Italy
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by the presence of arterial and venous thrombosis, and by recurrent abortions, in patients with persistent presence of autoantibodies…
Abstract Number: 3124 • 2015 ACR/ARHP Annual Meeting
Associations of Circulating Cell-Free Micro-RNA with Vasculopathy and Vascular Events in SLE Patients
Susan Due Kay¹, Anting L. Carlsen², Anne Voss¹, Mikael Kjær Poulsen³, Axel Cosmus Pyndt Diederichsen⁴ and Niels H. H. Heegaard⁵, ¹Department of Rheumatology, Odense University Hospital, Odense C, Denmark, ²Department of Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark, ³Department of Cardiology, Odense University Hospital, Odense C, Denmark, ⁴Department of Cardiology,, Odense University Hospital, Odense C, Denmark, ⁵Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense C, Denmark
Background/Purpose: MicroRNAs (miRNAs) are small noncoding RNAs that modulate protein translation and regulate numerous immunologic and inflammatory pathways. Certain miRNA profiles have been associated with…
Abstract Number: 2003 • 2015 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome Is Characterized By Endothelial Progenitor Dysfunction and a Type I Interferon Signature
Robert C. Grenn¹, Srilakshmi Yalavarthi², Paula L. Bockenstedt³ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI
Background/Purpose: Patients with primary antiphospholipid syndrome (APS) are at risk for endothelial dysfunction and accelerated atherosclerosis. In systemic lupus erythematosus (SLE), there is a well-established…
Abstract Number: 2005 • 2015 ACR/ARHP Annual Meeting
Circulating Mirnas As Potential Disease Biomarkers in Antiphospholipid Syndrome Patients
Carlos Perez-Sanchez¹, Mihaela Diana Ivanoiu¹, Maria Ángeles Aguirre Zamorano¹, Patricia Ruiz-Limon¹, Nuria Barbarroja¹, Yolanda Jiménez Gómez¹, Maria Carmen Abalos-Aguilera¹, Rocio Gonzalez-Conejero², Constantino Martinez², Eduardo Collantes-Estevez¹, Mª Jose Cuadrado³ and Chary Lopez-Pedrera¹, ¹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²Regional Centre for Blood Donation, University of Murcia, Murcia, Spain, ³Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom
Background/Purpose: Epigenetic anomalies are emerging as striking pathogenic features of autoimmune disorders. MicroRNAs (miRNAs) are small non-coding RNAs with a key role in regulatory networks that…
Abstract Number: 2174 • 2015 ACR/ARHP Annual Meeting
Neutrophils in Primary Antiphospholipid Syndrome Are Characterized By a Prominent Activated Phenotype and Uniquely Remodeled Chromatin Architecture
Patrick Coit, Srilakshmi Yalavarthi, Jason S. Knight and Amr H. Sawalha, Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by recurrent thrombotic events, pregnancy complications, and the presence of antiphospholipid antibodies. The pathogenesis of…
Abstract Number: 2175 • 2015 ACR/ARHP Annual Meeting
Comparative Study Between Coagucheck XS Versus Standard Laboratory Practice Protrombine Time for Monitoring Anticoagulant Therapy in Patients with Antiphospholipid Syndrome
Maria Ester Simeira Fonseca¹, Michelle Lopes², Christiane Pereira Gouvea³ and Danieli Andrade⁴, ¹Rheumatology, University of São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ³Hematology, University of São Paulo, São Paulo, Brazil, ⁴Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY
Background/Purpose: Antiphospholipid Syndrome (APS) is an autoimmune disease characterized by antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although initially described in patients with systemic lupus erythematosus (SLE) it…
Abstract Number: 2178 • 2015 ACR/ARHP Annual Meeting
Oxidation of beta2-Glycoprotein I (beta2-GPI) Associates with the Presence of Antibodies to Domain I of beta2-GPI in Patients with the Antiphospholipid Syndrome but Is Not Affected By the Antibodies in Vivo in a Rat Model
Maria Gabriella Raimondo^1,2, Charis Pericleous³, Anna Radziszewska^4,5, Maria Orietta Borghi^6,7, Silvia S. Pierangeli⁸, Pier Luigi Meroni^6,9, Ian Giles³, Anisur Rahman³ and Yiannis Ioannou^3,10, ¹Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ²Centre for Rheumatology Research, UCL Division of Medicine, University College London, London, United Kingdom, ³Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ⁴The Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁵The Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ⁶Department of Clinical Sciences and Community Health, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁷Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁸Rheumatology/Internal Medicine, University of Texas Medical Branch, Galveston, TX, ⁹Immunorheumatology Research Laboratory, IRCCS Istituto Auxologico Italiano, Cusano Milanino (mi), Italy, ¹⁰Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology, UCL Division of Medicine, London, United Kingdom
Background/Purpose: β2GPI represents the major antigenic target for antiphospholipid antibodies (aPL), the hallmark of antiphospholipid syndrome (APS). β2GPI contains five homologous domains, with domain I…
Abstract Number: 2180 • 2015 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome Patients Display Increased Levels of Cell-Bound C4d in Comparison to SLE and Healthy Donors
Maria Gerosa^1,2, Paola Adele Lonati³, Tania Ubiali¹, Martina Cornalba¹, Maria Orietta Borghi^1,4 and Pier Luigi Meroni^1,2,5, ¹Department of Clinical Sciences and Community Health, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ²Division of Rheumatology, Division of Rheumatology, Istituto Ortopedico Gaetano Pini, Milan, Italy, ³Laboratory of Immuno-rheumatology, Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Jamaica, ⁴Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁵Laboratory of Immuno-rheumatology, Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Italy
Background/Purpose: Systemic Lupus Erythematosus (SLE) patients display high levels of the cell-bound complement activation factor C4d deposits on erythrocytes, B lymphocytes and platelets. In particular,…
Abstract Number: 1980 • 2014 ACR/ARHP Annual Meeting
Thrombospondin-1 Is Elevetad in the Plasma of Patients with Antiphospholipid Syndrome and Is Correlated with Soluble Fas Ligand and Free Active TGF-B levels
Markos Patsouras¹, Marina Sikara², Athanasios G. Tzioufas² and Panayiotis Vlachoyiannopoulos², ¹PATHOPHYSIOLOGY DEPARTMENT, UNIVERSITY OF ATHENS, School of Medicine, National University of Athens, Athens, Greece, ²Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose Antiphospholipid syndrome (APS) is an acquired thombophillia characterized by recurrent thromboembolism and pregnancy morbidity. Thrombospondin (TSP-1) is a matricellular glycoprotein with antiangiogenic and proapoptotic…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].